BS_K25F4J3V
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 8.935611038107753
- age_years
- 2.263
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.677
- MYC_TARGETS_V1+0.627
- G2M_CHECKPOINT+0.579
- MYC_TARGETS_V2+0.525
- DNA_REPAIR+0.400
- WNT_BETA_CATENIN_SIGNALING+0.375
- UNFOLDED_PROTEIN_RESPONSE+0.275
- SPERMATOGENESIS+0.187
- MITOTIC_SPINDLE+0.173
- NOTCH_SIGNALING+0.096
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.641
- INTERFERON_GAMMA_RESPONSE-0.593
- IL6_JAK_STAT3_SIGNALING-0.591
- ALLOGRAFT_REJECTION-0.563
- TNFA_SIGNALING_VIA_NFKB-0.549
- INFLAMMATORY_RESPONSE-0.530
- COMPLEMENT-0.492
- COAGULATION-0.440
- KRAS_SIGNALING_UP-0.425
- MYOGENESIS-0.423
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_N6N147BY | Embryonal tumors | — | 0.960 |
| 2 | BS_5P1TN10Z | Embryonal tumors | — | 0.956 |
| 3 | SRR12696755 | — | — | 0.944 |
| 4 | TCGA-56-7223-01A-11R-2045-07 | — | cohortMD1 | 0.940 |
| 5 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.939 |
| 6 | SRR13780247 | — | cohortMD1 | 0.939 |
| 7 | C3L-01285 | — | cohortSQ2 | 0.934 |
| 8 | BS_JZRM1S3T | medulloblastoma | — | 0.932 |
| 9 | BS_FBJ5Q54N | Embryonal tumors | — | 0.932 |
| 10 | SAMN03290918 | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.677 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.627 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.579 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.525 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.375 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.275 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.187 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.173 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.096 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.069 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.015 | Inavolisib | — uncovered |